# Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).

> **NCT03647722** · — · TERMINATED · sponsor: **University of Southern California** · enrollment: 97 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** Assessment of leukocyte function.

## Key facts

- **NCT ID:** NCT03647722
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-02
- **Primary completion:** 2020-11-01
- **Final completion:** 2020-11-30
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Study funding was terminated.
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647722, "Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03647722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*